Search

everythinglearnresearchcommunity

for

Search:↓

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The user is pleased with their hair growth results after using oral minoxidil (2.5mg) for 3 months and finasteride (1mg) for 4 months, despite experiencing significant shedding initially. They prefer oral treatments over topical due to convenience and concerns about toxicity to pets.

The user started using 1mg oral finasteride a year ago and added oral minoxidil 3-4 months ago, experiencing no side effects except initial aching. They found oral minoxidil more effective for regrowth and easier than topical due to its toxicity to dogs.

Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.

Minoxidil is highly toxic to cats, and even small amounts can be fatal. The user decided against using topical minoxidil due to the risk to their cats and considered oral minoxidil and ketoconazole shampoo as alternatives.

OP has been using oral minoxidil (5mg) and oral dutasteride (0.5mg) but sees little progress and is unsure if they should continue. Other users suggest being consistent, giving it more time, and addressing scalp inflammation.

User considers scalp micropigmentation (SMP) for hair loss. Mixed opinions shared; some regret it, others satisfied. Choosing reputable clinic and technician is important.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

Piroctone Olamine at 1% is recommended for reducing scalp inflammation and encouraging hair growth. The user seeks recommendations for UK shampoos/conditioners containing this ingredient.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.

Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.

User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.

The user has been using 1mg finasteride and 2.5mg oral minoxidil for three months, noticing new blonde hairs but experiencing ongoing shedding. They also use GHK-Cu, which has improved skin but not hair.

Minoxidil is highly toxic to cats, and users are advised to avoid using it if they have cats, or to take extreme precautions if they do. Some users suggest using oral minoxidil instead, but it may not be available in all countries.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user started using homemade topical finasteride with PG-free liquid minoxidil for hair loss. They noticed the solution became milky with floaters and asked if it needed filtering.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

After 8 months of using oral Minoxidil 5mg and Finasteride 1mg, the user still experiences hair loss, particularly miniaturized hairs in the mid-scalp area, along with itching. They are concerned about losing around 40 hairs daily despite treatment.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

User shared 18-month progress using 1 mg finasteride daily and varying doses of oral minoxidil. Minoxidil caused side effects managed with taurine, dandelion root, sauna, and collagen.

A user shared their hair loss progress after 2 years of finasteride and 1 year of minoxidil, along with occasional microneedling and regular exercise. They experienced initial shedding but saw significant improvement after 4 months.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.